Business
Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study
ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study First head-to-head, double-blind, randomized phase 4 study powered to directly compare the tolerability profiles of these vaccines in adults in a real-world settingResults were presented today at the European Society of Clinical Microbiology and Infectious Diseases Global Congress in Munich, Germany. Paris, April 18, 2026. Sanofi's protein-based non-mRNA COVID-19 vaccine Nuvaxovid (NVX-CoV
About this update from Sanofi Sa
[{"type":"image","alt":"Sanofi Winthrop Industrie","displaySize":"","headline":null,"caption":"Sanofi Winthrop Industrie","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":84,"url":"https://media.zenfs.com/en/globenewswire.com/c45c40f5ed741dd9c0f5c2f75b8fc137"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/739gYr0oCQk4PhnczLgzIQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOA--/https://media.zenfs.com/en/globenewswire.com/c45c40f5ed741dd9c0f5c2f75b8fc137","width":300,"height":84}},"lazy":false},{"type":"text","content":"ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study","length":111,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"First head-to-head, double-blind, randomized phase 4 study powered to directly compare the tolerability profiles of these vaccines in adults in a real-world setting","length":164,"tagName":"p"}]},{"val":[{"type":"text","content":"Results were presented today at the European Society of Clinical Microbiology and Infectious Diseases Global Congress in Munich, Germany.","length":152,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":316,"olType":false},{"type":"text","content":"Paris, April 18, 2026. Sanofi's protein-based non-mRNA COVID-19 vaccine Nuvaxovid (NVX-CoV2705) demonstrated statistically significant lower systemic reactogenicity (the expected side effects that might occur following vaccination) compared to mNEXSPIKE (mRNA-1283), Moderna's latest mRNA COVID-19 vaccine, across all pre-specified endpoints in the COMPARE study. The randomized, double-blind study, which enrolled 1,000 adults in the US, was presented at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, Germany.","length":578,"tagName":"p"},{"type":"text","content":"These results address a persistent challenge: despite the end of the pandemic, COVID-19 continues to cause significant hospitalizations and deaths globally, while placing considerable strain on health systems during seasonal peaks. Yet vaccination uptake remains low, with concerns about vaccine side effects ranking among the top reasons cited by adults for not getting vaccinated against COVID-19.","length":399,"tagName":"p"},{"type":"text","content":"In the COMPARE study, when side effects did o...